S Peters

Alectinib versus crizotinib in previously untreated ALK-positive gevorderd non-small cell lung cancer: final totale o...

Annals of oncology : official journal of the European Society for Medical Oncology · 2026-01

Early and locally gevorderd non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and...

Annals of oncology : official journal of the European Society for Medical Oncology · 2025-11

Circulating tumor DNA clearance as a predictive biomarker of pathologic complete response in patiënten met solid tumo...

Annals of oncology : official journal of the European Society for Medical Oncology · 2025-07

A randomised phase III study of bevacizumab and carboplatin-pemetrexed chemotherapy with or without atezolizumab as e...

Annals of oncology : official journal of the European Society for Medical Oncology · 2025-05

Sitravatinib plus nivolumab versus docetaxel bij plaveiselcel NSCLC: SAPPHIRE fase III

Annals of oncology : official journal of the European Society for Medical Oncology · 2024-01

Niet-oncogeen-gedreven gemetastaseerd NSCLC: ESMO 2023 richtlijn

Annals of oncology : official journal of the European Society for Medical Oncology · 2023-04

Oncogeen-gedreven gemetastaseerd NSCLC: ESMO 2023 richtlijn

Annals of oncology : official journal of the European Society for Medical Oncology · 2023-04

Nivolumab plus ipilimumab versus chemotherapie als eerstelijns bij mesothelioom: CheckMate 743 langetermijn

Annals of oncology : official journal of the European Society for Medical Oncology · 2022-05

EGFR-gemuteerd NSCLC: ESMO expertconsensus

Annals of oncology : official journal of the European Society for Medical Oncology · 2022-05

Osimertinib plus bevacizumab versus osimertinib als tweedelijns bij T790M NSCLC: fase II

Annals of oncology : official journal of the European Society for Medical Oncology · 2022-02

Consolidatieve nivolumab-ipilimumab versus observatie bij limited-stage SCLC: STIMULI fase II

Annals of oncology : official journal of the European Society for Medical Oncology · 2022-01

Pan-Aziatische ESMO-richtlijn voor CRC: diagnostiek, behandeling en follow-up

Annals of oncology : official journal of the European Society for Medical Oncology · 2021-12

Hersenmetastasen: EANO-ESMO 2021 richtlijn

Annals of oncology : official journal of the European Society for Medical Oncology · 2021-11

Kleincellig longcarcinoom: ESMO 2021 richtlijn

Annals of oncology : official journal of the European Society for Medical Oncology · 2021-07

Tweedelijns nivolumab bij recidief SCLC: CheckMate 331 fase III

Annals of oncology : official journal of the European Society for Medical Oncology · 2021-05

Pembrolizumab versus chemotherapie als tweedelijns bij NSCLC: KEYNOTE-010 definitieve OS

Annals of oncology : official journal of the European Society for Medical Oncology · 2020-12

Geactualiseerde OS en PFS van CheckMate 214: nivolumab-ipilimumab bij mRCC

Annals of oncology : official journal of the European Society for Medical Oncology · 2020-08

Pan-Aziatische ESMO-richtlijn voor lokaal gevorderd NSCLC

Annals of oncology : official journal of the European Society for Medical Oncology · 2020-02

Pan-Aziatische ESMO-richtlijn voor gemetastaseerd NSCLC

Annals of oncology : official journal of the European Society for Medical Oncology · 1 februari 2019

Alectinib versus crizotinib bij ALK-positief NSCLC: ALEX geactualiseerde analyse

Annals of oncology : official journal of the European Society for Medical Oncology · 1 november 2018

Gemetastaseerd NSCLC: ESMO 2018 richtlijn update

Annals of oncology : official journal of the European Society for Medical Oncology · 1 oktober 2018

Vroeg en lokaal gevorderd NSCLC: ESMO-richtlijn voor diagnostiek, behandeling en follow-up

Annals of oncology : official journal of the European Society for Medical Oncology · 1 juli 2017